Hypothesis

Sequential priming with a transient, subclinical innate immune stimulus (e.g., low‑dose TLR4 agonist) synchronizes senescent cells into a cGAS‑STING‑high, SASP‑primed state that markedly increases their susceptibility to senosensitizer‑senolytic combinations, thereby overcoming the 30‑70% clearance ceiling observed with current regimens.

Rationale

• Senolytics such as dasatinib + quercetin (D+Q) clear only a fraction of senescent cells because resistant subpopulations require environmental triggers to become vulnerable 4.
• Cytoplasmic DNA fragments that activate the cGAS‑STING pathway drive the SASP, which in turn reinforces senescence and creates a feed‑forward loop 5.
• Infection‑associated danger signals (e.g., LPS, viral nucleic acids) transiently elevate cGAS‑STING activity in nearby cells, potentially pushing senescent cells over a threshold where anti‑apoptotic BCL‑2 dependencies are weakened and ferroptosis sensitisation is enhanced.
• Combining a brief innate immune trigger with a senosensitizer (e.g., a BCL‑2 inhibitor or ferroptosis inducer) followed by a senolytic could therefore convert resistant senescent cells into a uniformly vulnerable phenotype.

Predictions

1. In human peripheral blood mononuclear cells (PBMCs) ex‑posed to low‑dose LPS (10 ng/mL, 4 h) followed by dasatinib + quercetin, the proportion of senescent cells (identified by p16^INK4a^ and SA‑β‑gal) will decrease by ≥2‑fold compared to D+Q alone (p < 0.01).
2. SASP biomarkers (IL‑6, CXCL10, MMP7) in the supernatant will show a greater reduction after the priming‑senolytic sequence than after senolytic alone.
3. The effect will be abrogated by pretreatment with a cGAS inhibitor (e.g., RU.521) or STING‑blocking oligonucleotide, confirming pathway dependence.
4. In a murine model of accelerated aging, a biweekly regimen of low‑dose LPS → D+Q will extend healthspan metrics (grip strength, frailty index) more effectively than D+Q alone, without increasing organ toxicity.

Experimental Design

In vitro

• Isolate PBMCs from healthy donors, induce senescence via etoposide (10 µM, 48 h).
• Randomise to: (i) vehicle, (ii) D+Q (dasatinib 10 nM + quercetin 5 µM, 24 h), (iii) LPS priming (10 ng/mL, 4 h) → D+Q, (iv) LPS priming + cGAS inhibitor → D+Q, (v) LPS priming + ferroptosis inhibitor (liproxstatin‑1) → D+Q.
• Assess senescence (flow cytometry for p16, SA‑β‑gal imaging), viability (Annexin V/PI), and SASP (ELISA for IL‑6, CXCL10, MMP7).

Ex vivo human tissue

• Use precision‑cut lung slices from donors with mild COPD; treat as above and measure senescent cell burden via immunofluorescence for p21 and SASP mRNA (qPCR).

In vivo

• Ercc1^−/− progeroid mice receive biweekly low‑dose LPS (0.5 mg/kg i.p.) followed 24 h later by D+Q (dasatinib 5 mg/kg + quercetin 30 mg/kg oral) for 8 weeks.
• Controls: vehicle, D+Q alone, LPS alone.
• Primary endpoints: grip strength, treadmill endurance, frailty score; secondary: tissue‑specific senescent cell burden (p16^INK4a^‑GFP reporter), plasma SASP, histology for organ toxicity.

Potential Pitfalls

• Over‑stimulation of innate immunity could exacerbate inflammation; dose‑finding studies must confirm transient, subclinical activation (e.g., no sustained fever or cytokine storm).
• Heterogeneity of senescent cell origins may yield variable cGAS‑STING responsiveness; single‑cell RNA‑seq priming signatures will be needed to identify responsive subpopulations.
• Translational safety of repeated LPS exposure in humans requires careful monitoring; alternatives such as microbiome‑derived muramyl dipeptide or synthetic STING agonists with short half‑lives could be explored.

If the priming step fails to augment senescent cell clearance or if cGAS/STING inhibition does not abrogate the effect, the hypothesis would be falsified, indicating that infection‑linked innate immune signals are not a necessary synchronizer for senolytic susceptibility.

References

[1] https://lifespan.io/news/results-of-a-phase-1-trial-of-senolytics-for-alzheimers/ [2] https://www.science.org/content/blog-post/senolytic-update [3] https://doi.org/10.1038/s41593-019-0372-9 [4] https://medicalxpress.com/news/2026-02-preclinical-senolytics-zombie-cells.html [5] https://pmc.ncbi.nlm.nih.gov/articles/PMC8976373/ [6] https://doi.org/10.1038/s41422-020-0314-9 [7] https://www.eurekalert.org/news-releases/1119814 [8] https://www.withpower.com/trial/phase-1-multiple-sclerosis-chronic-progressive-2026-c9c81 [9] https://www.nad.com/news/natural-compound-fisetin-combats-heart-disease-by-eliminating-senescent-cells-new-brown-university-study